<DOC>
	<DOC>NCT01075217</DOC>
	<brief_summary>No significant differences is expected in observed motion artifacts, heat or pain reported during peripheral DSA performed for diagnostic and/or endovascular therapeutic purposes.</brief_summary>
	<brief_title>Isovue in Peripheral Digital Subtraction Angiography (DSA)</brief_title>
	<detailed_description />
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>provides written informed consent; at least 18 years of age; scheduled to undergo peripheral DSA for the diagnosis and/or treatment of PAOD pregnant or lactating female; known allergies to one more more ingredients in wither product; history of severe congestive heart failure (Class IV); previously enrolled or received an investigational compound within 30 days; history of hypersensitivity to iodinated contrast agents; renal impairment eGFR &lt;60 mL/min/1.73m2, calculated using the MDRD study equation any other medical condition decreasing chances of obtaining reliable data</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Peripheral arterial occlusive disease (PAOD)</keyword>
</DOC>